The Scientist-to-Scientist (S2S) program is a premier customer experience designed to connect researchers worldwide with Thermo Fisher Scientific R&D bench scientists of established expertise. Facilitating discoveries in pharmaceutical, biotech, and academic laboratories, high-level S2S engagements usually start with face-to-face conversations and on-site seminars, but frequently continue with regular customer interactions as technical needs grow and change.
Download posters, guides, application notes, and videos today.
David’s Ph.D. and postdoctoral work focused on the study of G protein-coupled receptor pharmacology and thrombosis. Following his academic training, he led Luminex®-based multiplexed immunoassay platform development efforts at a Luminex® partnering company. In 2009, David joined Thermo Fisher Scientific (formerly Life Technologies) as a senior scientist working on the development of novel immunoassay platforms (e.g., ProtoPlex™ Immune Response Assay). Working on next-gen immunoassay technologies, David is interested in working with translational investigators and key opinion leaders to identify serum-based biomarkers in cancer, autoimmunity, and inflammation. Beyond his R&D responsibilities, David is dedicated to platform strategy and the Thermo Fisher Scientific antibody content roadmap.
- Biomarker discovery-to-validation
- Immunoassays for Inflammation, autoimmunity and cancer
- Cell signaling
- Immunoassay development
- Western blotting workflow
Translational investigators require powerful immunoassays for the targeted detection of proteomic biomarkers with the goal of improving human health. Serum profiling tools are critical to understanding how acute and chronic inflammatory conditions initiate diseases such as cancer and autoimmunity. Invitrogen™ immunoassay solutions from Thermo Fisher Scientific provide sensitive and specific detection of target proteins across a range of applications and platforms, including western blotting, ELISA, and Luminex™ xMAP™ multiplexed bead-based assays. This latter platform produces rich data sets from small sample volumes.
Born out of a need to validate ProtoArray® human protein microarray-based biomarker discovery results, and provide additional context around immune profiling, our multiplexed immunoassays now measure both halves of the serum proteome: antigens and autoantibodies. Targeted biomarker discovery and validation on the ProtoPlex™ platform utilizes the same trusted xMAP™ multiplexing technology found in our cytokine assays. This unique two-tiered approach has been used in the study autoimmune diseases including SLE. Data from our 30-plex Human Cytokine Panel and the ProtoPlex™ Autoimmune Panel (19-plex) will be discussed. Additionally, this seminar will highlight key capabilities and benefits of our immunoassay tools in the context of inflammatory cell signaling, cancer, and autoimmunity.